title: Post-transplant EBV-related lymphoproliferative disorder complicating umbilical cord blood transplantation in patients of adrenoleukodystrophy.
abstract: EBV-associated post-transplant lymphoproliferative disorder (PTLD) is a well-recognized complication following solid organ transplantation and hematopoietic stem cell transplantation (HSCT) using bone marrow or peripheral blood as stem cell sources, but rarely reported in umbilical cord blood transplantation (UCBT). We report two cases in unrelated UCBT setting and added the following new information to the literature: (i) EBV-related PTLD can be presented late in recipients of unrelated UCBT; (ii) in contrast to reported literatures that PTLD is a serious complication with unfavorable outcome, especially in monomorphic form, our cases showed that the clinical course may be relatively benign if treatment is initiated promptly.
authors: Department of Pediatrics, Lady Pao Children's Cancer Centre, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong. frankiecheng@cuhk.edu.hk
authors: Frankie Wai Tsoi
authors: FW
authors: Cheng
authors: Vincent
authors: V
authors: Lee
authors: Ka Fai
authors: KF
authors: To
authors: K C Allen
authors: KC
authors: Chan
authors: Ming Kong
authors: MK
authors: Shing
authors: Chi Kong
authors: CK
authors: Li
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use; D000326:Adrenoleukodystrophy / Q000150:complications / Q000601:surgery*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D036101:Cord Blood Stem Cell Transplantation; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000188:drug therapy; D006086:Graft vs Host Disease / Q000188:drug therapy; D004854:Herpesvirus 4, Human / Q000502:physiology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008232:Lymphoproliferative Disorders / Q000188:drug therapy / Q000209:etiology* / Q000628:therapy / Q000821:virology; D008297:Male; D011183:Postoperative Complications / Q000188:drug therapy / Q000209:etiology* / Q000628:therapy / Q000821:virology; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D000069283:Rituximab; D014412:Tumor Virus Infections / Q000150:complications* / Q000188:drug therapy; D014775:Virus Activation / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069283:Rituximab; D016572:Cyclosporine; D011239:Prednisolone; D000212:Acyclovir